New cystic fibrosis biotech aims to take a different approach than Vertex

http://www.bizjournals.com/

California-based Synedgen has spun out its experimental cystic fibrosis treatments into a new biotech to be based in the Boston area, with an eye toward complementing existing drugs for the lung disease. Continue reading New cystic fibrosis biotech aims to take a different approach than Vertex

Vertex Grants $1 Million to Non-Profits for Cystic Fibrosis

http://www.raredr.com/

Earlier today, Vertex Pharmaceuticals Incorporated – a corporation designed to fund scientific innovation to create transformative medicines for people with serious and life-threatening diseases – announced the grant recipients for its 2017 Cystic Fibrosis (CF) Circle of Care program. Continue reading Vertex Grants $1 Million to Non-Profits for Cystic Fibrosis

New cystic fibrosis drug (Vertex)

https://www.ft.com/content/aa944954-13f4-11e7-b0c1-37e417ee6c76

Combination treatment offers safer option for patients suffering from deadly illness

Vertex Pharmaceuticals said that a combination of two of its medicines had successfully treated cystic fibrosis in a closely watched clinical trial, paving the way for regulators to approve a Continue reading New cystic fibrosis drug (Vertex)

News about Concert Pharmaceuticals’ cystic fibrosis drug

http://cen.acs.org/articles/95/web/2017/03/Vertex-buys-Concerts-cystic-fibrosis-drug.htm

Vertex buys Concert’s cystic fibrosis drug
Vertex Pharmaceuticals will pay up to $250 million for Concert Pharmaceuticals’ cystic fibrosis drug CTP-656. Currently in Phase II clinical trials, the drug is a deuterated version of Vertex’s own Continue reading News about Concert Pharmaceuticals’ cystic fibrosis drug

Phase 2a CF corrector study

Galapagos doses first patient with novel CF corrector GLPG2222

Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of the first patient with cystic fibrosis (CF) Class III (F508del and a gating mutation like G551D) with novel CF corrector GLPG2222 as an add-on to Kalydeco®[1] in a Phase 2a study. Galapagos further announced the opening of an Investigational New Drug (IND) file with the US Food & Drug Administration for GLPG2222, triggering a $10 million milestone payment.
Continue reading Phase 2a CF corrector study

My Five Takeaways from #NACFC2016

I had a dream last night, and in that dream the Limp Bizkit classic song, Nookie was on repeat for some reason. I have no idea why; I haven’t heard that song in about 12 years. Needless to say I woke up pretty jacked up and motivated to get sh*t done before the Packers game this afternoon. Continue reading My Five Takeaways from #NACFC2016

Vertex to test new class of CF drugs

Vertex to test new class of cystic fibrosis drugs in patients

https://www.bostonglobe.com/business/2016/10/25/vertex-test-new-class-cystic-fibrosis-drugs-patients/IcwjZhIPc2YXyguss2OGSM/story.html

Vertex Pharmaceuticals Inc. said Tuesday it will begin clinical trials for a new class of “triple combination” drug candidates that could nearly double the Continue reading Vertex to test new class of CF drugs

Potential Treatment for Cystic Fibrosis

Catabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis at the 30th Annual North American Cystic Fibrosis Conference

http://www.pharmiweb.com/PressReleases/pressrel.asp?ROW_ID=187116#.WA6VFKOZO8U

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that CAT-5571, a novel activator Continue reading Potential Treatment for Cystic Fibrosis

Vertex to get new investment from CFF

Vertex to get new investment from Cystic Fibrosis Foundation

https://www.bostonglobe.com/business/2016/10/14/vertex-get-new-investment-from-cystic-fibrosis-foundation-under-revised-deal/XklbRNebBa1nOhgt4WOqFI/story.html

Vertex Pharmaceuticals Inc. will receive an upfront payment of $75 million and additional payments of up to $6 million a year for the development of new cystic Continue reading Vertex to get new investment from CFF

Vertex ends trial of cystic fibrosis drug combination

https://www.bostonglobe.com/business/2016/08/15/vertex-ends-trial-cystic-fibrosis-drug-combination/6AkHgBOmtKPF9XRgq18IQM/story.html

Vertex Pharmaceuticals Inc. said Monday it is ending a clinical study testing a two-drug combination therapy on a small group of cystic fibrosis patients after an independent board concluded the experimental treatment wasn’t showing Continue reading Vertex ends trial of cystic fibrosis drug combination